Eikon Therapeutics, Inc. (EIKN)
Nasdaq: EIKN · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2021
Who owns Eikon Therapeutics, Inc.
As filed with the SECHolders of 5% or more
6
Tim Kutzkey holds 11.6% of Common Stock, $0.0001 par value per share, as its SCHEDULE 13D filed Feb 12, 2026 says.
Directors and officers
11
report now, of 11 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Tim Kutzkey
SCHEDULE 13D · filed Feb 12, 2026 · Common Stock, $0.0001 par value per share
Fmr LLC
SCHEDULE 13G/A · filed Oct 7, 2026 · COMMON STOCK · 9.2% in Aug 6, 2026
James B. Tananbaum
SCHEDULE 13G · filed Feb 11, 2026 · Common Stock, par value $0.0001
BlackRock Portfolio Management LLC
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
Perlmutter Roger M
SCHEDULE 13G · filed May 13, 2026 · Common Stock, $0.0001 par value per share
Innovation Endeavors III LP
SCHEDULE 13G · filed May 15, 2026 · Common Stock, $0.0001 par value per share
Abu Dhabi Investment Authority
SCHEDULE 13G/A · filed Oct 2, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.2% in Feb 18, 2026
What EIKN reports owning in othersstakes of 5% or more, and other ties
Eikon Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
3purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$7.0Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 31 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Column Group Opportunity III, LP | 10% owner | 0 | $0 | 0 | 3 | $38.1M |
| Wolfe Josh | director | 0 | $0 | 0 | 2 | $5.0M |
| Frazier Kenneth C | director | 0 | $0 | 0 | 1 | $2.0M |
| Kutzkey Tim | 10% owner | 0 | $0 | 0 | 1 | $1.0M |
| Foresite Capital Opportunity Management V, LLC | 10% owner | 0 | $0 | 0 | 1 | $1.0M |